Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Peripheral T-cell Lymphomas
Join Steven Horwitz, MD and Laura Tang, PharmD, BCOP from Memorial Sloan Kettering Cancer Center as they present their expertise on a range of cases pertaining to peripheral T-cell lymphomas.
Peripheral T‑cell lymphomas (PTCL) are a heterogeneous group of aggressive non-Hodgkin’s lymphomas (NHL), accounting for about 10% of NHL. The most common subtypes include PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and anaplastic large cell lymphoma (ALCL). Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype occurring in less than 5% of patients. Anthracycline-based multiagent chemotherapy is the standard first-line therapy. However, with the exception of ALK-positive ALCL, other subtypes (PTCL-NOS, AITL and EATL) are associated with lower response rates to first-line chemotherapy alone and responses are not durable. Patients with these subtypes often receive high-dose therapy and autologous stem cell rescue (HDT/ASCR) following first-line therapy. Relapsed or refractory disease is managed with second-line chemotherapy followed by HDT/ASCR or allogeneic stem cell transplant, based on the patient’s eligibility for transplant but treatment for this group of patients remains suboptimal.
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Review the current therapeutic options for the treatment of newly diagnosed and relapsed/refractory peripheral T-cell lymphomas.
- Develop an individualized treatment plan that integrates novel treatment options for the management of patients with relapsed/refractory peripheral T-cell lymphomas.
- Counsel patients with peripheral T-cell lymphomas about available clinical trials.
Steven Horwitz, MD
Memorial Sloan Kettering Cancer Center
Laura Tang, PharmD, BCOP
Memorial Sloan Kettering Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below discloses no relevant financial relationships:
Laura Tang, PharmD, BCOP
The faculty listed below discloses the following relevant financial relationships:
Steven M. Horwitz, MD
Amgen: Grant/Research Support
Celgene Corporation: Consulting Fees, Honoraria, Grant/Research Support
Huya Bioscience International: Consulting Fees, Honoraria
Infinity Pharmaceuticals, Inc.: Consulting Fees, Honoraria, Grant/Research Support
Kyowa Hakko Kirin Co., Ltd.: Scientific Advisor, Grant/Research Support
Millennium Pharmaceuticals, Inc.: Scientific Advisor, Grant/Research Support
Seattle Genetics, Inc.: Consulting Fees, Honoararia, Grant/Research Support
Genentech, Inc.: Grant/Research Support
Spectrum Pharmaceuticals: Grant/Research Support
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN (employed by NCCN until 2/7/17); Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser (employed by NCCN until 2/3/17)
The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Hema Sundar, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity code: I00026235; Approval Number: 170001242
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-17-024-L01-P
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation